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In early stages of drug development there is often
uncertainty about the most promising among a set of
different treatments. In order to ensure the best use of
resources it is important to decide which, if any, of the
treatments should be taken forward for further testing.
Multi-arm multi-stage (MAMS) trials provide gains in
efficiency over separate randomised trials of each treat-
ment. They allow a shared control group, dropping of
ineffective treatments before the end of the trial and
stopping the trial early if sufficient evidence of a treat-
ment being superior to control is found. Moreover a
direct, head-to-head, comparison of treatments is under-
taken that ensures that many potentially influential out-
side factors are eliminated.
In this talk we discuss optimal MAMS designs for
normally distributed endpoints. An optimal design has
the required type I error rate and power, but mini-
mises the expected sample size (ESS) at some combi-
nation of treatment effects. Finding an optimal design
requires searching over the stopping boundaries and
sample size per stage, potentially a large number of
parameters. We propose a method which combines
quick evaluation of specific designs and an efficient
stochastic search for the optimal design parameters.
The search can also take the allocation ratio between
controls and active treatments into account, allowing
further efficiency gains.
In the two-arm case, the triangular design has excel-
lent expected sample size properties, and is immediate
to find. Here we find that there is potential for greater
improvements over the triangular design, especially as
the number of stages or active treatments increases. The
triangular design still serves as a quick-to-find and near-
optimal design, so may still be useful for design of
MAMS trials.
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